REG - Craven House Capital - Investee Companies' Update: Bio Vitos

Craven House CapitalAnnouncement

05/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240605:nRSE1196Ra&default-theme=true

RNS Number : 1196R  Craven House Capital PLC  05 June 2024

Craven House Capital PLC

5 June 2024

 

Certain information contained within this Announcement is deemed by the
Company to constitute inside information as stipulated under the Market Abuse
Regulation (EU) No. 596/2014 ("MAR") as applied in the United Kingdom. Upon
publication of this Announcement, this information is now considered to be in
the public domain.

Craven House Capital plc

("Craven House" or the "Company")

Investee Companies' Update: Bio Vitos

 

Further to the announcement on 28 November 2023, Craven House was allocated a
pro-rata distribution of c.63,615,230 shares by Bio Vitos Medical Limited in
Bio Vitos Pharma AB (previously known as Hemcheck Sweden AB). These shares
amounted to a market value, at the time, of c.12 million Swedish Kroner /
c.$1.136 US Dollars. 22,496,354 shares were sold to cover costs relating to
the transaction. Following settlement of the transaction Craven House has
received 41,118,876 shares in Bio Vitos Pharma AB, representing 15.4% of Bio
Vitos Pharma AB's issued share capital.

Craven House remains a 24.5% shareholder in Bio Vitos Medical Limited and now
owns 15.4% of Bio Vitos Pharma AB, a Sweden based medical technology company,
listed on the Stockholm stock exchange.

For further information please contact:

 Craven House Capital Plc                                                Tel: 0203 286 8130

 Mark Pajak

 www.Cravenhousecapital.com (http://www.cravenhousecapital.com/)

 SI Capital                                                              Tel: 01483 413500

 Broker

 Nick Emerson

 www.sicapital.co.uk (http://www.sicapital.co.uk/)

 SPARK Advisory Partners Limited                                         Tel: 0203 368 3550

 Nominated Adviser

 Matt Davis

 www.Sparkadvisorypartners.com (http://www.sparkadvisorypartners.com/)

 About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a
portfolio of companies, partnerships, joint ventures, businesses or other
assets participating in the e-Commerce sector.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDMZGGVNDMGDZM